BindingDB logo
myBDB logout

17 articles for thisTarget

The following articles (labelled with PubMed ID or TBD) are for your review
PMIDDataArticle TitleOrganization
27597413 58 Development of highly potent phosphodiesterase 4 inhibitors with anti-neuroinflammation potential: Design, synthesis, and structure-activity relationship study of catecholamides bearing aromatic rings.EBI Southern Medical University
27301679 21 Design and synthesis of potent and selective pyridazin-4(1H)-one-based PDE10A inhibitors interacting with Tyr683 in the PDE10A selectivity pocket.EBI Takeda Pharmaceutical Company Limited
26526739 35 Catecholic amides as potential selective phosphodiesterase 4D inhibitors: Design, synthesis, pharmacological evaluation and structure-activity relationships.EBI Southern Medical University
25815146 29 Pyrido[4,3-e][1,2,4]triazolo[4,3-a]pyrazines as Selective, Brain Penetrant Phosphodiesterase 2 (PDE2) Inhibitors.EBI Janssen Pharmaceutica N.V.
25801159 36 Discovery of novel pyrazolopyrimidinone analogs as potent inhibitors of phosphodiesterase type-5.EBI CSIR-Indian Institute of Integrative Medicine
25221665 33 Structure-Based Design of a Potent, Selective, and Brain Penetrating PDE2 Inhibitor with Demonstrated Target Engagement.EBI Janssen Pharmaceutica NV
22142545 96 Discovery of orally active pyrazoloquinolines as potent PDE10 inhibitors for the management of schizophrenia.EBI Merck Research Laboratories
21955943 47 Investigation of the pyrazinones as PDE5 inhibitors: evaluation of regioisomeric projections into the solvent region.EBI Pfizer Inc.
20196613 32 Design, synthesis, and biological evaluation of 3-[4-(2-hydroxyethyl)piperazin-1-yl]-7-(6-methoxypyridin-3-yl)-1-(2-propoxyethyl)pyrido[3,4-b]pyrazin-2(1H)-one, a potent, orally active, brain penetrant inhibitor of phosphodiesterase 5 (PDE5).EBI Pfizer Global Research and Development
19631533 126 Optimization of the aminopyridopyrazinones class of PDE5 inhibitors: discovery of 3-[(trans-4-hydroxycyclohexyl)amino]-7-(6-methoxypyridin-3-yl)-1-(2-propoxyethyl)pyrido[3,4-b]pyrazin-2(1H)-one.EBI Pfizer Global Research and Development
19339180 69 The discovery of potent, selective, and orally bioavailable PDE9 inhibitors as potential hypoglycemic agents.EBI Pfizer Global Research and Development
19303290 4 Discovery and structure-activity study of a novel benzoxaborole anti-inflammatory agent (AN2728) for the potential topical treatment of psoriasis and atopic dermatitis.EBI Anacor Pharmaceuticals, Inc